1
|
D'Souza C, Keam SP, Yeang HXA, Neeson M, Richardson K, Hsu AK, Canfield R, Bezman N, Robbins M, Quach H, Ritchie DS, Harrison SJ, Trapani JA, Prince HM, Beavis PA, Darcy PK, Neeson PJ. Myeloma natural killer cells are exhausted and have impaired regulation of activation. Haematologica 2021; 106:2522-2526. [PMID: 34011135 PMCID: PMC8409027 DOI: 10.3324/haematol.2020.277525] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2020] [Indexed: 11/09/2022] Open
Affiliation(s)
- Criselle D'Souza
- Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne.
| | - Simon P Keam
- Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia; Tumour Suppression and Cancer Sex Disparity Laboratory, Peter MacCallum Cancer Centre, Melbourne
| | | | - Michael Neeson
- Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne
| | | | - Andy K Hsu
- Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne
| | - Rachael Canfield
- Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne
| | - Natalie Bezman
- Oncology Discovery Research, Bristol-Myers Squibb, Redwood City, CA, USA. Current: Arsenal Bio, San Francisco, CA 94080
| | - Michael Robbins
- Translational Medicine, Bristol-Myers Squibb, Cambridge, MA, USA, (current: io904 LLC)
| | - Hang Quach
- Department of Hematology, St Vincent's Hospital, Melbourne, Australia; Faculty of Medicine, University of Melbourne
| | - David S Ritchie
- Tumour Suppression and Cancer Sex Disparity Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia; Faculty of Medicine, University of Melbourne, Australia; Clinical Hematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne
| | - Simon J Harrison
- Tumour Suppression and Cancer Sex Disparity Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia; Clinical Hematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne
| | - Joseph A Trapani
- Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne
| | - H Miles Prince
- Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia; Clinical Hematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne
| | - Paul A Beavis
- Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne
| | - Phillip K Darcy
- Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne
| | - Paul J Neeson
- Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne.
| |
Collapse
|
2
|
Nguyen T, Kocovski N, Macdonald S, Yeang HXA, Wang M, Neeson PJ. Multiplex Immunohistochemistry Analysis of Melanoma Tumor-Infiltrating Lymphocytes. Methods Mol Biol 2021; 2265:557-572. [PMID: 33704740 DOI: 10.1007/978-1-0716-1205-7_39] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Tumor-infiltrating lymphocytes (TILs) are an important prognostic indicator in melanoma and play a key role in the patient's response to immune checkpoint blockade. However, until recently, it was not possible to combine multi-parameter markers to define the TILs and their histological context. Multiplex immunohistochemistry (mIHC) is a new technology which addresses this issue and enables simultaneous detection of melanoma and multiple immune subsets in formalin fixed paraffin embedded tissue. Following antigen retrieval, melanoma tissue sections are stained by OPAL on an autostainer, including serial rounds of epitope labelling with monoclonal antibodies followed by tyramide signal amplification (TSA). The stained tissue sections are then imaged on the Vectra instrument, and digital images are processed by analysis software (inForm and HALO) to derive tissue segmentation and immune subset densities within the tumor and tumor stroma. Spatial relationships between immune cells and tumor cells are then analyzed using a novel R algorithm. Taken together, multiplex IHC describes the histological context of the immune system in melanoma. The data is objective and allows for characterization of individual melanomas as T cell inflamed (hot), immune excluded, or no immune cells (cold).
Collapse
Affiliation(s)
- Thu Nguyen
- Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
| | - Nikolce Kocovski
- Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
| | - Sean Macdonald
- Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
| | - Han Xian Aw Yeang
- Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
- Sir Peter MacCallum Department of Oncology, Parkville, VIC, Australia
| | - Minyu Wang
- Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
- Sir Peter MacCallum Department of Oncology, Parkville, VIC, Australia
| | - Paul J Neeson
- Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
- Sir Peter MacCallum Department of Oncology, Parkville, VIC, Australia.
| |
Collapse
|
3
|
Williams SG, Aw Yeang HX, Mitchell C, Caramia F, Byrne DJ, Fox SB, Haupt S, Schittenhelm RB, Neeson PJ, Haupt Y, Keam SP. Immune molecular profiling of a multiresistant primary prostate cancer with a neuroendocrine-like phenotype: a case report. BMC Urol 2020; 20:171. [PMID: 33115461 PMCID: PMC7592533 DOI: 10.1186/s12894-020-00738-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2020] [Accepted: 10/06/2020] [Indexed: 02/06/2023] Open
Abstract
Background Understanding the drivers of recurrence in aggressive prostate cancer requires detailed molecular and genomic understanding in order to aid therapeutic interventions.
We provide here a case report of histological, transcriptional, proteomic, immunological, and genomic features in a longitudinal study of multiple biopsies from diagnosis, through treatment, and subsequent recurrence.
Case presentation Here we present a case study of a male in 70 s with high-grade clinically-localised acinar adenocarcinoma treated with definitive hormone therapy and radiotherapy. The patient progressed rapidly with rising PSA and succumbed without metastasis 52 months after diagnosis.
We identified the expression of canonical histological markers of neuroendocrine PC (NEPC) including synaptophysin, neuron-specific enolase and thyroid transcription factor 1, as well as intact AR expression, in the recurrent disease only.
The resistant disease was also marked by an extremely low immune infiltrate, extensive genomic chromosomal aberrations, and overactivity in molecular hallmarks of NEPC disease including Aurora kinase and E2F, as well as novel alterations in the cMYB pathway. We also observed that responses to both primary treatments (high dose-rate brachytherapy and androgen deprivation therapies) were consistent with known optimal responses—ruling out treatment inefficacy as a factor in relapse.
Conclusions These data provide novel insights into a case of locally recurrent aggressive prostate cancer harbouring NEPC pathology, in the absence of detected metastasis.
Collapse
Affiliation(s)
- Scott G Williams
- Division of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia.,Tumor Suppression Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia.,Pathology Department, Peter MacCallum Cancer Centre, Melbourne, Australia
| | - Han Xian Aw Yeang
- Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.,Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia
| | - Catherine Mitchell
- Pathology Department, Peter MacCallum Cancer Centre, Melbourne, Australia
| | - Franco Caramia
- Tumor Suppression Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia
| | - David J Byrne
- Pathology Department, Peter MacCallum Cancer Centre, Melbourne, Australia
| | - Stephen B Fox
- Pathology Department, Peter MacCallum Cancer Centre, Melbourne, Australia
| | - Sue Haupt
- Tumor Suppression Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia.,Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia
| | - Ralf B Schittenhelm
- Monash Proteomics & Metabolomics Facility, Monash University, Melbourne, Australia.,Department of Biochemistry and Molecular Biology, Monash University, Melbourne, Australia
| | - Paul J Neeson
- Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.,Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia
| | - Ygal Haupt
- Tumor Suppression Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia.,Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.,Department of Biochemistry and Molecular Biology, Monash University, Melbourne, Australia
| | - Simon P Keam
- Tumor Suppression Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia. .,Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia. .,Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
| |
Collapse
|
4
|
Wang M, Huang YK, Kong JC, Sun Y, Tantalo DG, Yeang HXA, Ying L, Yan F, Xu D, Halse H, Di Costanzo N, Gordon IR, Mitchell C, Mackay LK, Busuttil RA, Neeson PJ, Boussioutas A. High-dimensional analyses reveal a distinct role of T-cell subsets in the immune microenvironment of gastric cancer. Clin Transl Immunology 2020; 9:e1127. [PMID: 32377339 PMCID: PMC7200219 DOI: 10.1002/cti2.1127] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2020] [Revised: 03/26/2020] [Accepted: 03/27/2020] [Indexed: 12/18/2022] Open
Abstract
Objectives To facilitate disease prognosis and improve precise immunotherapy of gastric cancer (GC) patients, a comprehensive study integrating immune cellular and molecular analyses on tumor tissues and peripheral blood was performed. Methods The association of GC patients' outcomes and the immune context of their tumors was explored using multiplex immunohistochemistry (mIHC) and transcriptome profiling. Potential immune dysfunction mechanism/s in the tumors on the systemic level was further examined using mass cytometry (CyTOF) in complementary peripheral blood from selected patients. GC cohorts with mIHC and gene expression profiling data were also used as validation cohorts. Results Increased CD4+FOXP3+ T-cell density in the GC tumor correlated with prolonged survival. Interestingly, CD4+FOXP3+ T cells had a close interaction with CD8+ T cells rather than tumor cells. High densities of CD4+FOXP3+ T cells and CD8+ T cells (High-High) independently predicted prolonged patient survival. Furthermore, the interferon-gamma (IFN-γ) gene signature and PDL1 expression were up-regulated in this group. Importantly, a subgroup of genomically stable (GS) tumors and tumors with chromosomal instability (CIN) within this High-High group also had excellent survival. The High-High GS/CIN tumors were coupled with increased frequencies of Tbet+CD4+ T cells and central memory CD4+ T cells in the peripheral blood. Conclusion These novel findings identify the combination of CD8+ T cells and FOXP3+CD4+ T cells as a significant prognostic marker for GC patients, which also could potentially be targeted and applied in the combination therapy with immune checkpoint blockades in precision medicine.
Collapse
Affiliation(s)
- Minyu Wang
- Upper Gastrointestinal Translational Research Laboratory Peter MacCallum Cancer Centre Melbourne VIC Australia.,Sir Peter MacCallum Department of Oncology The University of Melbourne Melbourne VIC Australia.,Department of Medicine, Royal Melbourne Hospital The University of Melbourne Melbourne VIC Australia.,Cancer Immunology Research Peter MacCallum Cancer Centre Melbourne VIC Australia
| | - Yu-Kuan Huang
- Upper Gastrointestinal Translational Research Laboratory Peter MacCallum Cancer Centre Melbourne VIC Australia.,Sir Peter MacCallum Department of Oncology The University of Melbourne Melbourne VIC Australia.,Department of Medicine, Royal Melbourne Hospital The University of Melbourne Melbourne VIC Australia
| | - Joseph Ch Kong
- Sir Peter MacCallum Department of Oncology The University of Melbourne Melbourne VIC Australia.,Department of Medicine, Royal Melbourne Hospital The University of Melbourne Melbourne VIC Australia
| | - Yu Sun
- Sir Peter MacCallum Department of Oncology The University of Melbourne Melbourne VIC Australia
| | - Daniela G Tantalo
- Cancer Immunology Research Peter MacCallum Cancer Centre Melbourne VIC Australia
| | - Han Xian Aw Yeang
- Cancer Immunology Research Peter MacCallum Cancer Centre Melbourne VIC Australia
| | - Le Ying
- Centre for Innate Immunity and Infectious Diseases Hudson Institute of Medical Research Clayton VIC Australia
| | - Feng Yan
- Australian Centre for Blood Diseases Central Clinical School Monash University Melbourne VIC Australia
| | - Dakang Xu
- Faculty of Medical Laboratory Science Ruijin Hospital School of Medicine Shanghai Jiao Tong University Shanghai China
| | - Heloise Halse
- Cancer Immunology Research Peter MacCallum Cancer Centre Melbourne VIC Australia
| | - Natasha Di Costanzo
- Upper Gastrointestinal Translational Research Laboratory Peter MacCallum Cancer Centre Melbourne VIC Australia
| | - Ian R Gordon
- Statistical Consulting Centre School of Mathematics and Statistics The University of Melbourne Melbourne VIC Australia
| | - Catherine Mitchell
- Department of Pathology Peter MacCallum Cancer Centre Melbourne VIC Australia
| | - Laura K Mackay
- Department of Microbiology and Immunology Peter Doherty Institute for Infection and Immunity University of Melbourne Melbourne VIC Australia
| | - Rita A Busuttil
- Upper Gastrointestinal Translational Research Laboratory Peter MacCallum Cancer Centre Melbourne VIC Australia.,Sir Peter MacCallum Department of Oncology The University of Melbourne Melbourne VIC Australia.,Department of Medicine, Royal Melbourne Hospital The University of Melbourne Melbourne VIC Australia
| | - Paul J Neeson
- Sir Peter MacCallum Department of Oncology The University of Melbourne Melbourne VIC Australia.,Cancer Immunology Research Peter MacCallum Cancer Centre Melbourne VIC Australia.,Department of Pathology The University of Melbourne Melbourne VIC Australia
| | - Alex Boussioutas
- Upper Gastrointestinal Translational Research Laboratory Peter MacCallum Cancer Centre Melbourne VIC Australia.,Sir Peter MacCallum Department of Oncology The University of Melbourne Melbourne VIC Australia.,Department of Medicine, Royal Melbourne Hospital The University of Melbourne Melbourne VIC Australia
| |
Collapse
|
5
|
Hochheiser K, Aw Yeang HX, Wagner T, Tutuka C, Behren A, Waithman J, Angel C, Neeson PJ, Gebhardt T, Gyorki DE. Accumulation of CD103 + CD8 + T cells in a cutaneous melanoma micrometastasis. Clin Transl Immunology 2019; 8:e1100. [PMID: 31885869 PMCID: PMC6931001 DOI: 10.1002/cti2.1100] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2019] [Revised: 12/05/2019] [Accepted: 12/05/2019] [Indexed: 12/22/2022] Open
Abstract
Objective The immune system can halt cancer progression by suppressing outgrowth of clinically occult micrometastases in a state of cancer-immune equilibrium. Cutaneous melanoma provides a unique opportunity to study the immune contexture of such lesions, as miniscule skin metastases are accessible to clinical inspection and diagnostic biopsy. Methods Here, we analysed by multiplex immunofluorescence microscopy samples from a melanoma patient presenting with an overt and an occult in-transit metastasis (ITM), the latter of which appeared as a small erythematous papule. Results Microarchitecture and immune composition in the two lesions were vastly different. CD4+ and CD8+ T cells accumulated around the margin of the overt SOX10+ Melan A+ ITM but were largely excluded from the tumor centre. By contrast, the occult micrometastasis contained only few SOX10+ Melan A- melanoma cells which were scattered within a dense infiltrate of T cells, including a prominent population of CD103+ CD8+ T cells resembling tissue-resident memory T (TRM) cells. Notably, almost every single melanoma cell in the micrometastasis was in close proximity to these TRM-like cells. Conclusion Such results support the emerging concept that CD103+ CD8+ TRM cells are key mediators of cancer surveillance and imply an important function of these cells in controlling clinically occult micrometastases in humans.
Collapse
Affiliation(s)
- Katharina Hochheiser
- Peter MacCallum Cancer Centre Melbourne VIC Australia.,Department of Microbiology & Immunology The University of Melbourne at the Peter Doherty Institute for Infection & Immunity Melbourne VIC Australia
| | - Han Xian Aw Yeang
- Peter MacCallum Cancer Centre Melbourne VIC Australia.,Sir Peter MacCallum Department of Oncology The University of Melbourne Parkville VIC Australia
| | - Teagan Wagner
- Department of Microbiology & Immunology The University of Melbourne at the Peter Doherty Institute for Infection & Immunity Melbourne VIC Australia.,Telethon Kids Institute University of Western Australia Perth WA Australia
| | - Candani Tutuka
- Olivia Newton-John Cancer Research Institute Heidelberg VIC Australia
| | - Andreas Behren
- Olivia Newton-John Cancer Research Institute Heidelberg VIC Australia
| | - Jason Waithman
- Telethon Kids Institute University of Western Australia Perth WA Australia
| | | | - Paul J Neeson
- Peter MacCallum Cancer Centre Melbourne VIC Australia.,Sir Peter MacCallum Department of Oncology The University of Melbourne Parkville VIC Australia
| | - Thomas Gebhardt
- Department of Microbiology & Immunology The University of Melbourne at the Peter Doherty Institute for Infection & Immunity Melbourne VIC Australia
| | - David E Gyorki
- Peter MacCallum Cancer Centre Melbourne VIC Australia.,Department of Surgery University of Melbourne Melbourne VIC Australia
| |
Collapse
|
6
|
Thaventhiran T, Wong W, Alghanem AF, Alhumeed N, Aljasir MA, Ramsey S, Sethu S, Yeang HXA, Chadwick AE, Cross M, Webb SD, Djouhri L, Ball C, Stebbings R, Sathish JG. CD28 Superagonistic Activation of T Cells Induces a Tumor Cell-Like Metabolic Program. Monoclon Antib Immunodiagn Immunother 2019; 38:60-69. [PMID: 31009338 PMCID: PMC6634261 DOI: 10.1089/mab.2018.0042] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
CD28 superagonist (CD28SA), a therapeutic immunomodulatory monoclonal antibody triggered rapid and exaggerated activation of CD4+ effector memory T cells (TEMs) in humans with unwanted serious adverse effects. It is well known that distinct metabolic programs determine the fate and responses of immune cells. In this study, we show that human CD4+ TEMs stimulated with CD28SA adopt a metabolic program similar to those of tumor cells with enhanced glucose utilization, lipid biosynthesis, and proliferation in hypoxic conditions. Identification of metabolic profiles underlying hyperactive T cell activation would provide a platform to test safety of immunostimulatory antibodies.
Collapse
Affiliation(s)
- Thilipan Thaventhiran
- 1 Medical Research Council Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom
| | - Wai Wong
- 1 Medical Research Council Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom
| | - Ahmad F Alghanem
- 1 Medical Research Council Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom
| | - Naif Alhumeed
- 1 Medical Research Council Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom
| | - Mohammad A Aljasir
- 1 Medical Research Council Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom
| | - Simeon Ramsey
- 2 Inflammation and Remodeling, Pfizer Research Unit, Cambridge, Massachusetts
| | - Swaminathan Sethu
- 1 Medical Research Council Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom
| | - Han Xian Aw Yeang
- 1 Medical Research Council Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom
| | - Amy E Chadwick
- 1 Medical Research Council Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom
| | - Michael Cross
- 1 Medical Research Council Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom
| | - Steven D Webb
- 1 Medical Research Council Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom
| | - Laiche Djouhri
- 3 Department of Physiology, College of Medicine, King Saud University, Riyadh, Saudi Arabia
| | - Christina Ball
- 4 National Institute for Biological Standards and Control, Hertfordshire, United Kingdom
| | - Richard Stebbings
- 4 National Institute for Biological Standards and Control, Hertfordshire, United Kingdom
| | - Jean G Sathish
- 1 Medical Research Council Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom
| |
Collapse
|
7
|
Aw Yeang HX, Piersma SJ, Lin Y, Yang L, Malkova ON, Miner C, Krupnick AS, Chapman WC, Yokoyama WM. Cutting Edge: Human CD49e- NK Cells Are Tissue Resident in the Liver. J Immunol 2017; 198:1417-1422. [PMID: 28093522 DOI: 10.4049/jimmunol.1601818] [Citation(s) in RCA: 57] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/26/2016] [Accepted: 12/19/2016] [Indexed: 11/19/2022]
Abstract
Most knowledge on NK cells is based on studies of what are now known as conventional NK cells in the mouse spleen or human peripheral blood. However, recent studies in mice indicate the presence of tissue-resident NK cells in certain organs, such as the liver, that display different markers and transcription factor dependencies as compared with conventional NK cells. In this study, we provide evidence from cytometry by time-of-flight analysis and humanized mice indicating that human CD49e- NK cells are tissue resident in the liver. Thus, these studies indicate that tissue-resident NK cells are evolutionarily conserved in humans and mice, providing a foundation to explore their role in human disease.
Collapse
Affiliation(s)
- Han Xian Aw Yeang
- Division of Rheumatology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110
| | - Sytse J Piersma
- Division of Rheumatology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110
| | - Yiing Lin
- Division of Transplant Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO 63110
| | - Liping Yang
- Division of Rheumatology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110
| | - Olga N Malkova
- Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, St. Louis, MO 63110
| | - Cathrine Miner
- Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, St. Louis, MO 63110
| | - Alexander S Krupnick
- Department of Surgery, Washington University School of Medicine, St. Louis, MO 63110; and
| | - William C Chapman
- Division of Transplant Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO 63110
| | - Wayne M Yokoyama
- Division of Rheumatology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110; .,Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, St. Louis, MO 63110.,Howard Hughes Medical Institute, Washington University School of Medicine, St. Louis, MO 63110
| |
Collapse
|
8
|
Yeang HXA, Lin Y, Malkova ON, Yang L, Piersma SJ, Miner C, Oh ST, Chapman W, Yokoyama WM. Human liver contains two populations of NK cells based on CD49e expression. The Journal of Immunology 2016. [DOI: 10.4049/jimmunol.196.supp.194.7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Abstract
Natural killer cells are a subset of innate immune lymphocytes that can kill transformed and infected cells, and produce cytokines that modulate the host immune response. Previous studies on human NK cells have primarily characterized NK cells isolated from peripheral blood. However, studies in mice from our lab and others indicate an additional tissue-resident NK (trNK) population that does not re-circulate in contrast to conventional NK (cNK). When the mouse liver was excised and flushed with saline, trNK cells were detected, indicating that the trNK cells reside in the liver sinusoidal space. Recent studies to identify trNK cells in the human liver have concentrated on the differential expression of CD56-dim/bright populations of NK cells and also CD49a, a marker we previously defined for mouse trNK cells in the liver. Herein we obtained samples from liver transplantation cadaveric donors. Matching donor venous blood and serial liver saline flushes were studied. Our preliminary data identifies a subset of putative liver-trNK cells based on lack of CD49e expression which appeared in the terminal liver flush aliquot and was not present in earlier liver flushes nor peripheral blood whereas CD49a expression was not discriminatory. Mass cytometry experiments with cytometry by time-of-flight instrument and a panel of 42 antibodies corroborated these findings. Interestingly, the liver-resident CD49e− cells have elevated EOMES but lower Tbet expression which contrasts the CD49a+ trNK cell populations in human and mouse liver. Finally, the putative trNK cells express different killer immunoglobulin-like receptor (KIR) repertoire than cNK cells thus, a unique population of trNK cells that reside in the sinusoidal space of the human liver.
Collapse
|
9
|
Lauron EJ, Aw Yeang HX, Taffner SM, Sehgal RNM. De novo assembly and transcriptome analysis of Plasmodium gallinaceum identifies the Rh5 interacting protein (ripr), and reveals a lack of EBL and RH gene family diversification. Malar J 2015; 14:296. [PMID: 26243218 PMCID: PMC4524024 DOI: 10.1186/s12936-015-0814-0] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2015] [Accepted: 07/20/2015] [Indexed: 01/01/2023] Open
Abstract
Background Malaria parasites that infect birds can have narrow or broad host-tropisms. These differences in host specificity make avian malaria a useful model for studying the evolution and transmission of parasite assemblages across geographic ranges. The molecular mechanisms involved in host-specificity and the biology of avian malaria parasites in general are important aspects of malaria pathogenesis that warrant further examination. Here, the transcriptome of the malaria parasite Plasmodium gallinaceum was characterized to investigate the biology and the conservation of genes across various malaria parasite species. Methods The P. gallinaceum transcriptome was annotated and KEGG pathway mapping was performed. The ripr gene and orthologous genes that play critical roles in the purine salvage pathway were identified and characterized using bioinformatics and phylogenetic methods. Results Analysis of the transcriptome sequence database identified essential genes of the purine salvage pathway in P. gallinaceum that shared high sequence similarity to Plasmodium falciparum when compared to other mammalian Plasmodium spp. However, based on the current sequence data, there was a lack of orthologous genes that belonged to the erythrocyte-binding-like (EBL) and reticulocyte-binding-like homologue (RH) family in P. gallinaceum. In addition, an orthologue of the Rh5 interacting protein (ripr) was identified. Conclusions These findings suggest that the pathways involved in parasite red blood cell invasion are significantly different in avian Plasmodium parasites, but critical metabolic pathways are conserved throughout divergent Plasmodium taxa. Electronic supplementary material The online version of this article (doi:10.1186/s12936-015-0814-0) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Elvin J Lauron
- Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA.
| | - Han Xian Aw Yeang
- Rheumatology Division, Washington University School of Medicine, St. Louis, MO, USA.
| | - Samantha M Taffner
- Rheumatology Division, Washington University School of Medicine, St. Louis, MO, USA.
| | - Ravinder N M Sehgal
- Department of Biology, San Francisco State University, San Francisco, CA, USA.
| |
Collapse
|
10
|
Al-Huseini LMA, Aw Yeang HX, Hamdam JM, Sethu S, Alhumeed N, Wong W, Sathish JG. Heme oxygenase-1 regulates dendritic cell function through modulation of p38 MAPK-CREB/ATF1 signaling. J Biol Chem 2014; 289:16442-51. [PMID: 24719331 PMCID: PMC4047411 DOI: 10.1074/jbc.m113.532069] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Dendritic cells (DCs) are critical for the initiation of immune responses including activation of CD8 T cells. Intracellular reactive oxygen species (ROS) levels influence DC maturation and function. Intracellular heme, a product of catabolism of heme-containing metalloproteins, is a key inducer of ROS. Intracellular heme levels are regulated by heme oxygenase-1 (HO-1), which catalyzes the degradation of heme. Heme oxygenase-1 has been implicated in regulating DC maturation; however, its role in other DC functions is unclear. Furthermore, the signaling pathways modulated by HO-1 in DCs are unknown. In this study, we demonstrate that inhibition of HO-1 activity in murine bone marrow-derived immature DCs (iDCs) resulted in DCs with raised intracellular ROS levels, a mature phenotype, impaired phagocytic and endocytic function, and increased capacity to stimulate antigen-specific CD8 T cells. Interestingly, our results reveal that the increased ROS levels following HO-1 inhibition did not underlie the changes in phenotype and functions observed in these iDCs. Importantly, we show that the p38 mitogen-activated protein kinase (p38 MAPK), cAMP-responsive element binding protein (CREB), and activating transcription factor 1 (ATF1) pathway is involved in the mediation of the phenotypic and functional changes arising from HO-1 inhibition. Furthermore, up-regulation of HO-1 activity rendered iDCs refractory to lipopolysaccharide-induced activation of p38 MAPK-CREB/ATF1 pathway and DC maturation. Finally, we demonstrate that treatment of iDC with the HO-1 substrate, heme, recapitulates the effects that result from HO-1 inhibition. Based on these results, we conclude that HO-1 regulates DC maturation and function by modulating the p38 MAPK-CREB/ATF1 signaling axis.
Collapse
Affiliation(s)
- Laith M A Al-Huseini
- From the Medical Research Council (MRC) Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology, Sherrington Buildings, Ashton Street, University of Liverpool, Liverpool L69 3GE, United Kingdom and the Department of Pharmacology and Therapeutics, College of Medicine, Al-Qadisiyah University, P. O. Box 80, Diwaniyah 58001, Iraq
| | - Han Xian Aw Yeang
- From the Medical Research Council (MRC) Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology, Sherrington Buildings, Ashton Street, University of Liverpool, Liverpool L69 3GE, United Kingdom and
| | - Junnat M Hamdam
- From the Medical Research Council (MRC) Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology, Sherrington Buildings, Ashton Street, University of Liverpool, Liverpool L69 3GE, United Kingdom and
| | - Swaminathan Sethu
- From the Medical Research Council (MRC) Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology, Sherrington Buildings, Ashton Street, University of Liverpool, Liverpool L69 3GE, United Kingdom and
| | - Naif Alhumeed
- From the Medical Research Council (MRC) Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology, Sherrington Buildings, Ashton Street, University of Liverpool, Liverpool L69 3GE, United Kingdom and
| | - Wai Wong
- From the Medical Research Council (MRC) Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology, Sherrington Buildings, Ashton Street, University of Liverpool, Liverpool L69 3GE, United Kingdom and
| | - Jean G Sathish
- From the Medical Research Council (MRC) Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology, Sherrington Buildings, Ashton Street, University of Liverpool, Liverpool L69 3GE, United Kingdom and
| |
Collapse
|
11
|
Al-Huseini LMA, Aw Yeang HX, Sethu S, Alhumeed N, Hamdam JM, Tingle Y, Djouhri L, Kitteringham N, Park BK, Goldring CE, Sathish JG. Nuclear factor-erythroid 2 (NF-E2) p45-related factor-2 (Nrf2) modulates dendritic cell immune function through regulation of p38 MAPK-cAMP-responsive element binding protein/activating transcription factor 1 signaling. J Biol Chem 2013; 288:22281-8. [PMID: 23775080 PMCID: PMC3829319 DOI: 10.1074/jbc.m113.483420] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Nrf2 is a redox-responsive transcription factor that has been implicated in the regulation of DC immune function. Loss of Nrf2 results in increased co-stimulatory molecule expression, enhanced T cell stimulatory capacity, and increased reactive oxygen species (ROS) levels in murine immature DCs (iDCs). It is unknown whether altered immune function of Nrf2-deficient DCs (Nrf2−/− iDCs) is due to elevated ROS levels. Furthermore, it is unclear which intracellular signaling pathways are involved in Nrf2-mediated regulation of DC function. Using antioxidant vitamins to reset ROS levels in Nrf2−/− iDCs, we show that elevated ROS is not responsible for the altered phenotype and function of these DCs. Pharmacological inhibitors were used to explore the role of key MAPKs in mediating the altered phenotype and function in Nrf2−/− iDCs. We demonstrate that the increased co-stimulatory molecule expression (MHC II and CD86) and antigen-specific T cell activation capacity observed in Nrf2−/− iDCs was reversed by inhibition of p38 MAPK but not JNK. Importantly, we provide evidence for increased phosphorylation of cAMP-responsive element binding protein (CREB) and activating transcription factor 1 (ATF1), transcription factors that are downstream of p38 MAPK. The increased phosphorylation of CREB/ATF1 in Nrf2−/− iDCs was sensitive to p38 MAPK inhibition. We also show data to implicate heme oxygenase-1 as a potential molecular link between Nrf2 and CREB/ATF1. These results indicate that dysregulation of p38 MAPK-CREB/ATF1 signaling axis underlies the altered function and phenotype in Nrf2-deficient DCs. Our findings provide new insights into the mechanisms by which Nrf2 mediates regulation of DC function.
Collapse
Affiliation(s)
- Laith M A Al-Huseini
- Medical Research Council Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology, Sherrington Buildings, Ashton Street, University of Liverpool, Liverpool L69 3GE, United Kingdom
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Aw Yeang HX, Al-Huseini L, Sethu S, Hamdam J, Goldring C, Park K, Sathish J. Dysregulation in p38 signalling contributes to altered phenotype and function in Nrf2 deficient dendritic cells (P5025). The Journal of Immunology 2013. [DOI: 10.4049/jimmunol.190.supp.110.13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Abstract
Nrf2 is a redox sensitive transcription factor vital for the maintenance of cellular homeostasis. Dendritic cells (DCs) are potent APCs responsible for the initiation of an immune response. Our previous study highlights the role of Nrf2 in DC function (increased costimulatory receptors expression and T cell stimulatory capacity) and intracellular signaling (such as ROS, NFκB and MAPKs). The p38 MAPK pathway plays a pivotal role in the up regulation of costimulatory receptors (CD86 & MHC II). However, it is unclear how Nrf2 affects the integrity of this pathway. In the current study using bone marrow-derived immature DCs from Nrf2 deficient (KO) and wild type mice, we investigate the effect of Nrf2 on various signaling events in the p38 pathway and associated functional responses. Our results indicate that the loss of Nrf2 in DCs resulted in elevated basal p38 phosphorylation. Furthermore, an increase in basal phosphorylation of CREB and ATF-1 - downstream targets of p38, was also observed. This was coupled with increased IL-10 cytokine production at basal conditions and also upon exposure to LPS. Increased costimulatory receptor expression, antigen specific T cell activation propensity and LPS stimulated IL-10 production observed in the KO DCs can be reversed by pharmacological inhibition of p38. These results suggest that deficiency of Nrf2 in DCs leads to dysregulation of the p38 signaling pathway contributing to the altered phenotype and function of these DCs.
Collapse
Affiliation(s)
- Han Xian Aw Yeang
- 1Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom
| | - Laith Al-Huseini
- 1Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom
| | - Swaminathan Sethu
- 1Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom
| | - Junnat Hamdam
- 1Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom
| | - Christopher Goldring
- 1Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom
| | - Kevin Park
- 1Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom
| | - Jean Sathish
- 1Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom
| |
Collapse
|
13
|
Yeang HXA, Hamdam JM, Al-Huseini LMA, Sethu S, Djouhri L, Walsh J, Kitteringham N, Park BK, Goldring CE, Sathish JG. Loss of transcription factor nuclear factor-erythroid 2 (NF-E2) p45-related factor-2 (Nrf2) leads to dysregulation of immune functions, redox homeostasis, and intracellular signaling in dendritic cells. J Biol Chem 2012; 287:10556-10564. [PMID: 22311972 PMCID: PMC3322986 DOI: 10.1074/jbc.m111.322420] [Citation(s) in RCA: 56] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
Dendritic cells (DCs) are critical mediators of immunity and immune tolerance by orchestrating multiple aspects of T cell activation and function. Immature DCs (iDCs) expressing low levels of co-stimulatory receptors are highly efficient at antigen capture but are poor activators of T cells. Maturation of DCs is associated with increased expression of co-stimulatory molecules. Co-stimulatory receptor gene expression is regulated by intracellular redox, NF-κB, and MAPK pathways and by histone deacetylase (HDAC) activity. The transcription factor, Nrf2, is important for maintaining intracellular glutathione (GSH) levels and redox homeostasis and has been implicated in modulating DC co-stimulatory receptor expression. It is unclear whether Nrf2 mediates this effect by GSH-dependent mechanisms and whether it influences DC signaling pathways. Using bone marrow-derived iDCs from Nrf2+/+ and Nrf2−/− mice, we demonstrate that Nrf2−/− iDCs have lower basal GSH levels, enhanced co-stimulatory receptor expression, impaired phagocytic functions, and increased antigen-specific CD8 T cell stimulation capacity. Interestingly, lowering GSH levels in Nrf2+/+ iDCs did not recapitulate the Nrf2−/− iDC phenotype. Loss of Nrf2 resulted in elevated basal levels of reactive oxygen species but did not affect basal NF-κB activity or p38 MAPK phosphorylation. Using pharmacological inhibitors, we demonstrate that enhanced co-stimulatory receptor phenotype of Nrf2−/− iDC does not require ERK activity but is dependent on HDAC activity, indicating a potential interaction between Nrf2 function and HDAC. These results suggest that Nrf2 activity is required to counter rises in intracellular reactive oxygen species and to regulate pathways that control DC co-stimulatory receptor expression.
Collapse
Affiliation(s)
- Han Xian Aw Yeang
- Department of Pharmacology, Medical Research Council Centre for Drug Safety Science, University of Liverpool, Sherrington Buildings, Ashton Street, Liverpool L69 3GE, United Kingdom
| | - Junnat M Hamdam
- Department of Pharmacology, Medical Research Council Centre for Drug Safety Science, University of Liverpool, Sherrington Buildings, Ashton Street, Liverpool L69 3GE, United Kingdom
| | - Laith M A Al-Huseini
- Department of Pharmacology, Medical Research Council Centre for Drug Safety Science, University of Liverpool, Sherrington Buildings, Ashton Street, Liverpool L69 3GE, United Kingdom
| | - Swaminathan Sethu
- Department of Pharmacology, Medical Research Council Centre for Drug Safety Science, University of Liverpool, Sherrington Buildings, Ashton Street, Liverpool L69 3GE, United Kingdom
| | - Laiche Djouhri
- Department of Pharmacology, Medical Research Council Centre for Drug Safety Science, University of Liverpool, Sherrington Buildings, Ashton Street, Liverpool L69 3GE, United Kingdom
| | - Joanne Walsh
- Department of Pharmacology, Medical Research Council Centre for Drug Safety Science, University of Liverpool, Sherrington Buildings, Ashton Street, Liverpool L69 3GE, United Kingdom
| | - Neil Kitteringham
- Department of Pharmacology, Medical Research Council Centre for Drug Safety Science, University of Liverpool, Sherrington Buildings, Ashton Street, Liverpool L69 3GE, United Kingdom
| | - B Kevin Park
- Department of Pharmacology, Medical Research Council Centre for Drug Safety Science, University of Liverpool, Sherrington Buildings, Ashton Street, Liverpool L69 3GE, United Kingdom
| | - Christopher E Goldring
- Department of Pharmacology, Medical Research Council Centre for Drug Safety Science, University of Liverpool, Sherrington Buildings, Ashton Street, Liverpool L69 3GE, United Kingdom.
| | - Jean G Sathish
- Department of Pharmacology, Medical Research Council Centre for Drug Safety Science, University of Liverpool, Sherrington Buildings, Ashton Street, Liverpool L69 3GE, United Kingdom.
| |
Collapse
|